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Diadenosine Polyphosphates in Tears of Sjo¨gren
Syndrome Patients
Gonzalo Carracedo,1 Assumpta Peral,1 and Jesu´s Pintor2
PURPOSE. To analyze the levels of diadenosine tetraphosphate
(Ap4A) and diadenosine pentaphosphate (Ap5A) in tears of
subjects with Sjo¨gren syndrome and to compare them with
those in a control group.
METHODS. Twelve subjects with a diagnosis of Sjo¨gren syn-
drome and 20 healthy control subjects were invited to partic-
ipate in the present study. Schirmer strips were used to mea-
sure tear secretion (Schirmer I test) and to collect tears. Ap4A
and Ap5A were measured by high-pressure liquid chromatog-
raphy (HPLC), and a dry eye questionnaire (DEQ) was used to
evaluate dry eye symptomatology.
RESULTS. The mean concentrations of Ap4A and Ap5A in the
Sjo¨gren syndrome group were 2.54  1.02 and 26.13  6.95
M, respectively. This group of patients was divided in two
subgroups: four patients with normal tear production and eight
patients with low tear production. Concentrations of Ap4A,
and Ap5A in patients with normal tear production (Schirmer
test result, 12.3  1.2 mm) were 0.47  0.20 and 8.03  3.27
M, respectively. In the patients with low tear production
(Schirmer test result, 1.0  0.3 mm), the concentrations were
4.09  1.36 and 39.51  8.46 M, respectively and in the
control group, 0.13  0.03 and 0.04  0.02 M, respectively.
CONCLUSIONS. Patients with Sjo¨gren syndrome have abnormally
elevated concentrations of diadenosine polyphosphates, indi-
cating that these compounds could be used in the diagnosis of
this disease. (Invest Ophthalmol Vis Sci. 2010;51:5452–5459)
DOI:10.1167/iovs.09-5088
Sjo¨gren’s syndrome is a chronic autoimmune disease inwhich the body’s immune system mistakenly attacks its
own exocrine glands, particularly the salivary and the main
lachrymal glands. Lymphocytes infiltrate the glands and cause
a decrease in their secretions.1 This syndrome is classified as
primary when only the exocrine glands are affected and as
secondary when it is associated with other systemic diseases.2
Primary Sjo¨gren syndrome has a prevalence rate of 0.5% and
occurs more frequently in women than in men (9:1).3 It is
diagnosed late, usually at 45 to 50 years of age, most often in an
ophthalmologist’s or optometrist’s consulting room.4
Sjo¨gren patients report dry eye, sandy sensation, and irri-
tated eyes as common symptoms. The principal ocular signs of
the disease are aqueous tear deficiency and severe corneal
surface damage. It also presents systemic manifestations such
as xerostomia, dry skin and mouth, respiratory insufficiency,
and fatigue.1,5 At the beginning of the disease, when the typical
signs and symptoms are often lacking or are not entirely ex-
pressed, diagnosis is complicated. Ocular signs and identified
through assessment of tear production and ocular surface stain-
ing. It is also important to perform a test for dry eye symptom-
atology as suggested by the Dry Eye Workshop 2007.6 The
presence of the disease is fully confirmed by the presence of
systemic signs such as lymphocyte infiltration of the salivary
glands or the presence of antibody markers such as anti-Ro or
-La, together with the existence of at least one systemic symp-
tom such as dry mouth.2
The presence of diadenosine polyphosphates in the tear
film was described for the first time in 2002.7 These com-
pounds ApnA (n  2–7), formed by two adenosine molecules
joined by a variable phosphate chain, are naturally occurring
nucleotides with intra- and extracellular physiological actions.8
Since 2000, the activities of these nucleotides have been inves-
tigated in ocular tissues, and their involvements in some as-
pects of ocular physiology have been described.
In the tear film, it is known that diadenosine polyphosphate
concentrations rise in patients with dry eye symptoms, with
either normal or with low tear production, suggesting the
possibility that these compounds could be objective parame-
ters for grading dry eye.9 Moreover, a single-dose topical ap-
plication of the dinucleotides Ap4A, Ap5A, and Ap6A in rabbits,
can stimulate tear secretion, giving these compounds a secre-
tagogic action.10 Concerning the ocular surface, Ap4A im-
proves the rate of wound healing in the cornea of New Zealand
White rabbits.11 Also, intraocular pressure (IOP) can be mod-
ulated by the action of some dinucleotides in rabbits.12
The present experimental work describes variations in the
levels of diadenosine polyphosphates in Sjo¨gren syndrome
patients’ tears and how these compounds are abnormally in-
creased. Moreover, since Sjo¨gren syndrome diagnosis is inva-
sive and complex, it is suggested that the determination of
these dinucleotides would be a complementary approach that
can be used to prediagnose this disease.
METHODS
The study was conducted in compliance with good clinical practice
guidelines, institutional review board regulations, informed consent
regulations, and the tenets of the Declaration of Helsinki (World
Medical Association, 2008). All the subjects enrolled in the study were
adults older than 18 years and were able to give informed consent.
Subjects
Twelve subjects, 9 women and 3 men aged between 35 and 66 years
(mean, 52.8  4.2), who had received a diagnosis of primary Sjo¨gren
syndrome in the past 5 years (mean, 3.4  0.9) and were enrolled in
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the Spanish Sjo¨gren syndrome Society, participated voluntarily in the
study. In all the patients, the disease was diagnosed according to the
American-European Consensus Group (AECG) on diagnostic criteria
for Sjo¨gren syndrome (Vitali et al.2). This Sjo¨gren syndrome group was
divided into two subgroups, patients who had a Schirmer test result of
more than 5 mm (Sjo¨gren syndrome normal tear subgroup) and pa-
tients who had results below 5 mm (Sjo¨gren syndrome low tear
subgroup).
The control group constituted 11 female and 9 male healthy vol-
unteers aged between 34 and 63 years (mean 41.7  1.7), with no
evidence of dry eye symptoms or signs.
Schirmer strips were used to measure tear secretion (Schirmer I
test) and to collect tears. The measurements were made early in the
morning, before the instillation of any ocular medications. Every pa-
tient used artificial tears (Viscofresh 1%; Allergan, Irvine, CA) at least
five times per day. In addition, both groups were invited to complete
the Dry Eye Questionnaire (DEQ) developed by Begley et al.13
Trials
Tear Collection. Tear secretion was measured by using the
Schirmer I test (without anesthesia). The tear collection was always
performed according to Van Bijsterveld criteria.14 The Schirmer strip
was placed on the temporal tarsal conjunctiva of the lower lid for 5
minutes with the eyes closed. The volume of tears, in millimeters of
moistened strip, was recorded, and the Schirmer strips were placed in
tubes (Eppendorf, Fremont, CA) containing 500 L of purified water
(Ultrapure; Millipore, Billerica, MA). The samples were then frozen until
they were analyzed by high pressure liquid chromatography (HPLC).
Tear Processing and HPLC Analysis. After thawing, the
samples were strongly vortexed for 5 minutes. The strips were care-
fully rinsed, and the liquid in the tube was heated in a 100°C bath for
20 minutes, to precipitate the proteins. To pellet the proteins, we
centrifuged the tubes at 4000 rpm for 30 minutes. Diadenosine
polyphosphates are not degraded by this treatment, as previously
demonstrated.15 Supernatants were chromatographed16 through a sil-
ica-based hydrophilic anion exchanger (SEP-PAK Accell QMA cartridge;
Waters, Milford, MA). Briefly, 250 L of the supernatant was passed
through the cartridges which had been equilibrated with 3 mL of
distilled water. Elution of the nucleotides and dinucleotides was per-
formed by applying 1 mL of a solution containing 0.2 M KCl and 0.1 M
HCl. Before injection into the HPLC, the samples were neutralized with
KOH. The eluents were injected at a volume of 10 to 100 L.
Determination and quantification of diadenosine polyphosphates
were performed by HPLC. The chromatographic system consisted of
an isocratic HPLC pump (model 1515; Waters), a dual-absorbance
detector (model 2487; Waters), and an injector (Reodyne; Perkin
Elmer, Boston, MA), all managed by the software (Breeze; Waters). The
column was a C18, 15 cm in length, 0.4 cm in diameter (Novapack;
Waters). The system was equilibrated overnight with the following
mobile phase: 0.1 M KH2PO4, 2 mM tetrabutyl ammonium, and 17%
acetonitrile (pH 7.5).17 Detection was monitored at 260 nm wave-
length. All the peaks identified as putative dinucleotides were taken for
phosphodiesterase treatment. Phosphodiesterase from Crotalus ada-
manteus (EC 3.1.4.1) from Sigma-Aldrich (St. Louis, MO), at a concen-
tration of 1.0 U/mL, was incubated at room temperature for 30 minutes
with the corresponding putative dinucleotide. The digestion products
FIGURE 1. Demonstration of the
presence of diadenosine polyphos-
phates in tears of Sjo¨gren syndrome
patients. (A) Chromatographic pro-
file of a sample showing the pres-
ence of Ap4A and Ap5A in a sample of
tears from a Sjo¨gren syndrome pa-
tient. (B) Rechromatography of the
Ap4A shown in (A) after treatment
with phosphodiesterase, demon-
strating the cleavage of the dinucle-
otide and the formation of AMP and
ATP. (C) Ap5A from (A) after tre-
atment with phosphodiesterase
showing the appearance of AMP
and Ap4. (D) Standard injection of
commercial adenine mono- and
dinucleotides.
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were analyzed by HPLC. Peaks were transformed into concentrations
by means of external standards of known concentrations of diade-
nosine polyphosphates.
In the tear samples, two peaks were identified as Ap4A and Ap5A,
according to the retention times (Fig. 1A). To confirm the nature of the
putative Ap4A and Ap5A, both peaks were individually collected and
treated with phosphodiesterase from Crotalus adamanteus (Figs. 1B,
1C). The putative Ap4A produced two peaks after the enzyme action
that were identified as AMP and ATP, whereas the putative Ap5A
produced AMP and adenosine tetraphosphate. These results indicate
that these two original peaks corresponded to Ap4A and Ap5A. The
comparison of the peaks with the corresponding standards permitted
quantification of these two dinucleotides in the samples (Fig. 1D).
Dry Eye Questionnaire (DEQ)
This questionnaire was designed to assess the prevalence, frequency,
and diurnal severity of ocular surface symptoms such as discomfort,
dryness, visual changes, soreness, and irritation, grittiness and scratch-
iness, foreign body sensation, burning, light sensitivity, and itching. In
the first part of the questionnaire, inquiries regarding the frequency of
eight typical symptoms of dry eye were made, in which the patients
chose between four different frequencies (rarely, sometimes, fre-
quently, and constantly). The last part of the questionnaire includes
questions about computer use, allergies, use of systemic and ocular
medications, and ambient conditions that cause dry eye symptoms.13
The validation of the Spanish translation of the DEQ was supervised
by the Psychology Faculty of the Universidad Complutense de Madrid
and the original authors, Carolyn Begley and Robin Chalmers, who
verified with a Spanish translator the concordance between the English
and Spanish documents.
Statistical Analysis
The values presented are the mean  SEM of the experiments per-
formed (version 15.0 for Windows; SPSS, Inc., Chicago, IL). In the case
of Sjo¨gren syndrome subgroups values also are presented as the me-
dian (first quartile; third quartile). Normal distribution of variables was
assessed by the Kolmogorov-Smirnov normality test.
Sample size calculations were performed with statistical software
(Granmo 6.0; Institut Municipal d’Investigacio´n Me´dica, Barcelona,
Spain). With an accepted two-sided statistical significance threshold of
0.05 and a  risk of 0.20 and taking into account a 2:1 group ratio
(control group to Sjo¨gren syndrome group), 16 subjects were needed
in first group and 8 in the second, to find statistically significant
differences.
Differences between the Sjo¨gren syndrome and control groups in
diadenosine polyphosphates levels were estimated by the Student’s
t-test for independent samples. Because sample sizes of these groups
are small, Mann-Whitney U tests were used to compare values between
the Sjo¨gren subgroups.
Correlations between ordinal data in the Sjo¨gren syndrome group
were assessed by Pearson bivariate regression, and one-way analysis of
variance (ANOVA) was used to assess the correlation between diade-
nosine polyphosphate concentrations and each symptoms’ frequency.
For statistical analysis of DEQ symptoms data, we used the authors’
test criteria.13 These criteria indicate that patients who responded
frequently or constantly to the frequency questions were symptom-
atic. We regarded responses with a score of 4 or 5 to the questions
about intensity as signifying that the patient was experiencing intense
symptoms. The 2 test was used to contrast frequencies between
groups, and the Wilcoxon test was used to compare the diurnal
FIGURE 2. Schirmer I test in the
Sjo¨gren syndrome patients and nor-
mal subjects. Tear secretion was sig-
nificantly lower in the Sjo¨gren syn-
drome group than in the control
group. The Sjo¨gren syndrome group
could be split into two subgroups,
one with low tear secretion and one
with normal tear secretion. *P 
0.05, Student’s t-test.
TABLE 1. Concentrations of Nucleotides, Ap4A and Ap5A, in Control Group and Different Dry Eye
Group Severity
Control Group
(n  20)
Low Tear
SS Subgroup
(n  8)
Low Tear
Non-SS Group
(n  12)
Normal Tear
SS Subgroup
(n  4)
Normal Tear
Non-SS Subgroup
(n  34)
Ap4A 0.126 (0.027) 4.09 (1.36) 10.68 (0.54) 0.47 (0.20) 0.587 (0.058)
Ap5A 0.044 (0.023) 39.51 (8.45) 12.45 (0.08) 8.3 (3.27) 0.058 (0.003)
The data presented are mean micromolar concentrations of the two dinucleotides (SD). Groups have
been divided as normal or low tear production SS patients and compared with dry eye non-SS patients who
have normal or low tear production.9
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changes in symptom intensities (morning to evening). P  0.05 was
statistically significant.
RESULTS
Tear Volume Results
The tear volumes collected in the Sjo¨gren syndrome group
resulted in a mean Schirmer strip wetting result of 6  2.1 mm
(n  12). Four Sjo¨gren patients had a Schirmer test of more
than 5 mm (Sjo¨gren syndrome normal tear subgroup) and a
mean of 12.3  1.2 and median of 11 mm (10; 13), and eight
patients had results below 5 mm (Sjo¨gren syndrome low tear
volume subgroup), with a mean of 1.0  0.3 mm and median
of 0.75 mm (first and third quartiles: 0.50; 1.00; P  0.001;
Sjo¨gren syndrome low tear subgroup versus Sjo¨gren syndrome
normal tear subgroup; Mann-Whitney U test). The mean tear
volume in the control group was 19.9  2.3 mm (n  20; P 
0.001 control group versus Sjo¨gren syndrome group and con-
trol group versus Sjo¨gren syndrome normal tear subgroup;
Student’s t-test; Fig. 2).
Nucleotide Analysis in Tears
The mean concentrations of Ap4A, and Ap5A in the Sjo¨gren
syndrome group were 2.54  1.02 and 26.13  6.95 M,
respectively. In the subgroup of Sjo¨gren syndrome with normal
tear secretion (n  4), the concentrations of Ap4A and Ap5A
were 0.47  0.20 M (median, 0.41 M; first and third quar-
tiles, 0.12; 0.86) and 8.3  3.27 M (median, 6.4 M; 3.01;
14.60), respectively. The subgroup of Sjo¨gren syndrome with
low tear secretion (n 8) showed dinucleotide concentrations
of 4.09  1.36 M (median, 4.26 M; 0.23; 6.5) and 39.51 
8.45 M (median 36.6 M; 17.85; 59.14) for Ap4A and Ap5A,
respectively. These values were significantly different between
the subgroups (P  0.05 and P  0.02 for Ap4A and Ap5A,
respectively; Mann-Whitney U test). In the control group the
concentrations of Ap4A and Ap5A were 0.13 0.03 and 0.04
0.02 M, respectively (P 0.05 to Ap4A and P 0.01 to Ap5A;
control group versus Sjo¨gren syndrome group; Student’s t-test;
Table 1, Fig. 3).
DEQ Results
In the Sjo¨gren syndrome group, the most common responses
to all the symptoms were frequently or constantly. In patients
with Sjo¨gren syndrome who had a low tear volume, the most
frequent symptoms were eye discomfort, dry eyes, irritated
eyes, and sensitivity to light. In patients who had a normal tear
volume, all had symptoms of foreign body sensation, irritated
eyes, eye discomfort, and sensitivity to light. The results of the
FIGURE 3. Concentrations of Ap4A and Ap5A in the tears of Sjo¨gren syndrome patients and normal subjects. Data are presented for the control
group (n  20), Sjo¨gren syndrome group (n  12), and the two patient subgroups: normal (n  4) and low tear (n  8) production. *P  0.05
and †P  0.02 between Sjo¨gren syndrome subgroups, Wilcoxon Mann Whitney U test; *P  0.05 and †P  0.01 control versus Sjo¨gren syndrome
group, Student’s t-test.
TABLE 2. Frequency of Symptoms in Sjo¨gren Syndrome Patients
Sjo¨gren Syndrome
Symptom
Control Group
(n  20)
SS Group
(n  20)
Low Tear Subgroup
(n  8)
Normal Tear Subgroup
(n  4)
Discomfort 3 (15) 12 (100) 8 (100) 4 (100)
Dryness 1 (5) 9 (92) 8 (100) 3 (75)
Grittiness 0 (0) 6 (50) 5 (63) 1 (25)
Burning 0 (0) 5 (42) 4 (50) 1 (25)
Itching 1 (5) 7 (67) 5 (63) 3 (75)
Foreign body 0 (0) 8 (75) 5 (63) 4 (100)
Irritation 0 (0) 11 (92) 7 (88) 4 (100)
Light sensitivity 4 (20) 12 (100) 8 (100) 4 (100)
Blurring 1 (5) 6 (50) 5 (63) 1 (25)
Symptom distribution and frequency according to patients’ reports. The data are the number of
patients reporting the respective symptom and, in parentheses, the percentage of patients reporting that
symptom.
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control group are shown in Table 2. Significant differences
between the Sjo¨gren syndrome groups and control group were
observed (2 test, P  0.01).
Patients assessed the intensity of the symptoms on a scale
of 1 to 5, with 1 being the lowest and 5 the highest intensity,
and we deemed a symptom intense when patients reported
4 or 5, according to the DEQ authors’ criteria.13. In patients
with Sjo¨gren syndrome, symptoms such as discomfort, dry-
ness, foreign body, irritated eyes, and blurred vision in-
creased in intensity in the evening. The increase in patients
with intense symptoms was significantly greater in the low
tear subgroup than in the normal tear subgroup (Fig. 4). The
increase in the percentage of patients at the end of the day
in the subgroup of Sjo¨gren syndrome patients with low tears
was statistically significant (Wilcoxon test, P  0.05) for
four of eight symptoms studied. In contrast, in the normal
tears subgroup, there were no significant differences for any
symptom (Table 3). There were no daytime differences in
FIGURE 4. Percentage of patients
with intense dry eye symptoms at the
beginning and the end of the day.
Different aspects of the symptom-
atology were recorded, and the in-
tensity of the symptoms was scored
both in the morning and evening.
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the percentage of patients with intense symptoms for the
control group.
Correlations
In the Sjo¨gren syndrome group, the Pearson’s correlation co-
efficient was0.59 (P 0.002) for tear volume and Ap5A. The
value of this coefficient indicates a low to moderate degree of
correlation and the negative sign means that the lower the
result of the Schirmer test, the greater the level of Ap5A. With
respect to nucleotides, the Pearson’s correlation coefficient
showed a moderate to high degree of correlation for Ap4A (P
0.024) with Ap5A in the Sjo¨gren syndrome group (Table 4).
In a previous work, it was possible to demonstrate the
existence of differences between Ap4A and Ap5A concentra-
tions and symptomatic and asymptomatic dry eye patients.9 In
the present study, when trying to determine wether there
were differences between any reported symptom and the con-
centrations of these dinucleotides in Sjo¨gren syndrome pa-
tients, we did not find a statistically significant correlation
between any reported symptom and the concentrations of
these dinucleotides in Sjo¨gren syndrome patients by ANOVA
(P  0.05).
DISCUSSION
In the present work, the concentrations of Ap4A and Ap5A in
patients with Sjo¨gren syndrome were investigated. These val-
ues were increased 42- and 595-fold for Ap4A and Ap5A, re-
spectively, compared with the control group. In the Sjo¨gren
syndrome subgroup with low tear secretion, the results
showed that these patients had higher levels of the adenine
dinucleotides Ap4A and Ap5A in their tears than did Sjo¨gren
syndrome patients with normal tear secretion. These facts
could suggest that these dinucleotides are potential tools for
the diagnosis of dry eye, as previously related.9
If we compare the data of Sjo¨gren syndrome patients with
those of non-Sjo¨gren dry eye symptomatic subjects presented
in a previous work (Table 1),9 the concentration of Ap4A in
patients with Sjo¨gren syndrome with low tear secretion was
less than half that in those non-Sjo¨gren dry eye symptomatic
patients with reduced tear secretion. In the Sjo¨gren and the
non-Sjo¨gren dry eye groups with normal tear secretion, there
were no differences in the concentrations of Ap4A. However,
Ap5A appeared in higher concentrations in patients with
Sjo¨gren syndrome compared with non-Sjo¨gren dry eye sub-
jects. This fact could indicate that Ap5A can be a differentiating
factor between Sjo¨gren syndrome and non-Sjo¨gren dry eye.
Several works have reported that the ocular surface in
Sjo¨gren syndrome patients is altered and damaged. A positive
ocular staining with fluorescein and rose bengal has been
described in these subjects.18,19 The diadenosine polyphos-
phates have a hastening effect on the corneal re-epithelializa-
tion, and a greater release of Ap4A and Ap5A in tears will
therefore help naturally to facilitate the rate of wound heal-
ing.11 It has been reported that an increased blinking fre-
quency enhances the levels of nucleotides in tears, because of
the shear stress provoked by the eyelids on the ocular surface,9
and an increase in the blinking frequency of dry eye patients
has been reported.20 The damage to the ocular surface and the
increased blinking rate in Sjo¨gren syndrome patients could
explain why the presence of diadenosine polyphosphates in
these patients is higher than in healthy individuals.
TABLE 3. Results of Wilcoxon Signed-Rank Test Comparing the Diurnal Intensity of Symptoms
Sjo¨gren Syndrome
Symptom
Control Group
(n  20)
SS Group
(n  12)
SS Low Tear Subgroup
(n  8)
SS Normal Tear Subgroup
(n  4)
Discomfort 0.56 0.04* 0.01† 0.56
Dryness 0.66 0.31 0.02* 0.79
Grittiness —‡ 0.31 0.15 —‡
Burning —‡ 0.31 0.08 —‡
Itching 0.56 0.31 0.08 0.65
Foreign body —‡ 0.18 0.15 0.78
Irritation —‡ 0.04* 0.01† 0.41
Blurring 0.66 0.03* 0.01† 0.56
* P  0.05.
† P  0.01.
‡ Same intensity in the morning and evening in all patients.
TABLE 4. Correlation among Diadenosine Polyphosphates, Schirmer Test and Age in Sjo¨gren
Syndrome Patients
Ap4A Ap5A Schirmer Test Age
Ap4A Pearson correlation 1 0.76 0.43 0.12
P — 0.01* 0.11 0.67
Ap5A Pearson correlation 0.76 1 0.59 0.28
P 0.01* — 0.02† 0.32
Schirmer test Pearson correlation 0.43 0.59 1 0.20
P 0.11 0.02* — 0.41
Age Pearson correlation 0.12 0.28 0.20 1
P 0.67 0.32 0.41 —
Pearson bivariate regression test to compare the possible correlation among nucleotides, Schirmer
test and age.
* P  0.01 (two-tailed).
† P  0.05 (two-tailed).
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It has been shown that Ap4A and Ap5A stimulate tear
secretion,10 and it appears that they are naturally released
and serve to increase the tear volume and quality by stimu-
lating the P2Y2 receptors present in meibomian and acces-
sory glands.21,22 Although the presence of P2Y2 receptors in
the lacrimal gland has not yet been reported, these recep-
tors have been found in the lacrimal gland of New Zealand
White rabbit (Hoyle CHV, personal communication, 2009).
Their presence in the salivary glands has been demonstrated.23
Schrader et al.24 indicated that P2Y2 receptor expression is
upregulated in the submandibular gland of the NOD.B10
mouse, a model of Sjo¨gren syndrome, to provide a pathway
for fluid secretion. Furthermore, Baker et al.25 reported that
P2Y2 receptor activation in salivary gland cells increases the
epidermal growth factor receptor (EGFR)– dependent ex-
pression of vascular cell adhesion molecule (VCAM)-1 and
the binding of lymphocytes.
A similar effect may occur in the lacrimal gland of Sjo¨gren
syndrome patients, where the expression of the P2Y2 receptor
may be augmented to increase tear secretion, but in fact pro-
vokes the lymphocyte infiltration that may lead to the inflam-
mation associated with Sjo¨gren syndrome. Although Ap4A and
Ap5A are present at high concentrations in Sjo¨gren syndrome
patients, it seems to be that they are not able to stimulate more
lacrimation. Instead they may be increasing lymphocyte infil-
tration. Further studies are needed to confirm our hypothesis
that P2Y2 upregulation really occurs in lacrimal glands of
Sjo¨gren syndrome patients and to establish the purpose of this
upregulation.
In normal individuals dinucleoside polyphosphates increase
tear production.7 In contrast, some Sjo¨gren patients lack this
dinucleotide stimulation. Presumably, Sjo¨gren patients with
normal tear production have the benefit of the secretagogue
action triggered by these molecules, in clear contrast with
those who do not seem to be sensitive to these dinucleotides.
It could be the case that the difference between these two
subpopulations of Sjo¨gren patients is due to factors such as a
poorer tear quality that makes it more evaporative, or some
problems with the lachrymal apparatus. There is no evidence
of dysfunction of the P2Y2 receptors in the lachrymal gland,
but such dysfunction may explain the lack of secretagogue
activity for these substances in some Sjo¨gren patients. This
point should be investigated more thoroughly.
Concerning the Schirmer test results, it may be surprising
that in a disease whose main sign is aqueous tear deficiency,
patients have values of tear secretion above 10 mm. Others
studies have found similar results for the Schirmer test.18,19
This is probably due to the different severities of the disease
and the poor sensitivity of the test.26
Another interesting point is the lack of correspondence
between the increase in tear volume and the dinucleotide
concentration. The present experiments demonstrated that
when there was an increase in tear production, there was not
a linear change in the dinucleotide concentration. Indeed
dinucleotides were not “diluted” as expected, perhaps because
of the way these compounds are released. In particular, diade-
nosine polyphosphates are released as a consequence of me-
chanical stress,9 which very often relates to an increase in the
blinking frequency due to discomfort.9
Discomfort, light sensitivity, and dryness were the most
frequent and intense symptoms, which is consistent with the
results reported by other researchers.18 Sjo¨gren syndrome pa-
tients reported that their symptoms increased later in the day,
and they were more pronounced in the low tear secretion
group, Versura et al.27 suggested an environment or task-
related etiology for dry eye symptoms as the main factor in
increased intensity at the end of the day.
There were no statistically significant differences in Ap4A
and Ap5A concentrations in tears from normal humans aged
from 20 to 50 years (our unpublished data, 2010). Therefore,
the difference in ages of the control and Sjo¨gren syndrome
groups is not a factor in the difference in diadenosine polypho-
sphate concentrations.
In conclusion, concentrations of diadenosine polyphos-
phates are increased in tears of Sjo¨gren syndrome patients,
especially Ap5A, which could be used as a diagnostic tool for
this condition. In addition, we conclude that Ap4A is increased
in pathologic dry eye with respect to healthy eyes, confirming
its role as an objective marker of dry eye.
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